Clinical Value of 18 F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma.

MLA

Nakuz, Thomas Selim, et al. “Clinical Value of 18 F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma.” Anticancer Research, vol. 38, no. 1, Jan. 2018, pp. 353–58. EBSCOhost, https://doi.org/10.21873/anticanres.12229.

APA

Nakuz, T. S., Berger, E., El-Rabadi, K., Wadsak, W., Haug, A., Hacker, M., & Karanikas, G. (2018). Clinical Value of 18 F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. Anticancer Research, 38(1), 353–358. https://doi.org/10.21873/anticanres.12229

Chicago

Nakuz, Thomas Selim, Erik Berger, Karem El-Rabadi, Wolfgang Wadsak, Alexander Haug, Marcus Hacker, and Georgios Karanikas. 2018. “Clinical Value of 18 F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma.” Anticancer Research 38 (1): 353–58. doi:10.21873/anticanres.12229.